10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q2 2019

Filing Information

Form Type	10-Q
Accession Number	`0001532176-19-000026`
Period End Date	20190630
Filing Date	20190806
Fiscal Year	2019
Fiscal Period	Q2
XBRL Instance	regn-063019x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 67 Income Statement 80 Cash Flow Statement 54 Stockholders Equity 38

Balance Sheet 67 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.05B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$917.90M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.47B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.34B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.62B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.72B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.92B	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$226.40M	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$252.00M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$283.70M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$293.10M	USD	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	4.02M	shares	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	3.99M	shares	Point-in-time
Inventories	`InventoryNet`	$1.32B	USD	Point-in-time
Inventories	`InventoryNet`	$1.15B	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$208.20M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$243.30M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$6.45B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$6.65B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.75B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$2.88B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.58B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.68B	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$821.60M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$828.70M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$127.40M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$139.80M	USD	Point-in-time
Total assets	`Assets`	$11.73B	USD	Point-in-time
Total assets	`Assets`	$13.17B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$244.00M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$218.20M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$772.10M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$876.70M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.44B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.71B	USD	Point-in-time
Finance lease liabilities	`FinanceLeaseLiabilityNoncurrent`	$711.30M	USD	Point-in-time
Finance lease liabilities	`Capitalandfacilityleaseobligationsnoncurrent`	$708.50M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$267.90M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$361.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$3.42B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.98B	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.91B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.26B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$5.25B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$5.92B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$15.80M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.30M	USD	Point-in-time
Treasury Stock, at cost; 4,018,269 shares in 2019 and 3,990,021 shares in 2018	`TreasuryStockValue`	$441.80M	USD	Point-in-time
Treasury Stock, at cost; 4,018,269 shares in 2019 and 3,990,021 shares in 2018	`TreasuryStockValue`	$396.40M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.57B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$8.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.19B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.44B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.14B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$13.17B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$11.73B	USD	Point-in-time

Income Statement 80 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.65B	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.12B	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.61B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.93B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.03B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$529.30M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.69B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.05B	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$417.30M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$695.60M	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$364.80M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$828.10M	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$2.85B	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$985.80M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.93B	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$1.62B	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.19B	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$622.20M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$795.60M	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$315.60M	USD	1 Quarter
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$40.80M	USD	1 Quarter
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$-82.90M	USD	1 Quarter
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$-9.10M	USD	2 Qtrs
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$65.40M	USD	2 Qtrs
Interest expense	`InterestExpense`	$8.00M	USD	1 Quarter
Interest expense	`InterestExpense`	$15.70M	USD	2 Qtrs
Interest expense	`InterestExpense`	$13.30M	USD	2 Qtrs
Interest expense	`InterestExpense`	$6.90M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-90.90M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-24.80M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$52.10M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$33.90M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.24B	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$224.70M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$770.80M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$656.10M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$212.10M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$104.70M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$31.60M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$116.60M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$478.00M	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$1.77	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$9.56	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$6.00	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$5.12	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$8.97	USD	2 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$1.68	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$4.82	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.69	USD	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.70M	shares	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.20M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.10M	shares	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.80M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.60M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.00M	shares	2 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.50M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.70M	shares	2 Qtrs
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$478.00M	USD	1 Quarter
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$14.40M	USD	1 Quarter
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$3.40M	USD	1 Quarter
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-7.70M	USD	2 Qtrs
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$30.50M	USD	2 Qtrs
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-2.40M	USD	2 Qtrs
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-1.40M	USD	1 Quarter
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$2.00M	USD	2 Qtrs
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$600.00K	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$682.30M	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.02B	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$206.10M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$555.40M	USD	1 Quarter

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$478.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$70.00M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$103.10M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$213.70M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$189.20M	USD	2 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$-110.70M	USD	2 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$54.90M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$125.30M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$15.50M	USD	2 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$64.90M	USD	2 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$256.80M	USD	2 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$168.20M	USD	2 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$182.10M	USD	2 Qtrs
Decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-42.50M	USD	2 Qtrs
Decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-59.40M	USD	2 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-84.20M	USD	2 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$401.10M	USD	2 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$110.30M	USD	2 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$67.00M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$431.10M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-16.00M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.09B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.01B	USD	2 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$1.18B	USD	2 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$2.19B	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$745.90M	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$462.20M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$191.40M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$168.90M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-910.40M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.61B	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$155.10M	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$34.10M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$40.50M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$31.90M	USD	2 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$10.00M	USD	2 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$104.60M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.20M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-422.20M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$105.20M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.06B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.20M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$930.40M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.06B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.20M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$930.40M	USD	Point-in-time

Stockholders Equity 38 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$6.57B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$7.19B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$6.14B	USD	Point-in-time
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$140.90M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$13.90M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$19.80M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$13.60M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$10.70M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$31.90M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$29.70M	USD	1 Quarter
Issuance/distribution of Common Stock in connection with Company 401(k) Savings Plan	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$10.50M	USD	1 Quarter
Issuance/distribution of Common Stock in connection with Company 401(k) Savings Plan	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$-700.00K	USD	1 Quarter
Issuance/distribution of Common Stock in connection with Company 401(k) Savings Plan	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$11.70M	USD	1 Quarter
Repurchases of Common Stock from Sanofi	`TreasuryStockValueAcquiredCostMethod`	$54.00M	USD	1 Quarter
Repurchases of Common Stock from Sanofi	`TreasuryStockValueAcquiredCostMethod`	$37.60M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$109.20M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$113.10M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$114.80M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$85.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$478.00M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$15.10M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$4.10M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$13.00M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-9.70M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$6.57B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$7.19B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$6.14B	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.